KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Non Operating Income (2016 - 2025)

Sarepta Therapeutics has reported Non Operating Income over the past 15 years, most recently at -$5.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 152.93% year-over-year to -$5.3 million; the TTM value through Dec 2025 reached -$2.4 million, down 105.72%, while the annual FY2025 figure was -$2.4 million, 105.72% down from the prior year.
  • Non Operating Income for Q4 2025 was -$5.3 million at Sarepta Therapeutics, down from $48.0 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $301.1 million in Q4 2023 and troughed at -$83.1 million in Q1 2025.
  • A 5-year average of $14.2 million and a median of $3.0 million in 2022 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: tumbled 4077.59% in 2022 and later surged 5347.35% in 2023.
  • Year by year, Non Operating Income stood at -$16.1 million in 2021, then soared by 134.38% to $5.5 million in 2022, then surged by 5347.35% to $301.1 million in 2023, then plummeted by 96.66% to $10.1 million in 2024, then crashed by 152.93% to -$5.3 million in 2025.
  • Business Quant data shows Non Operating Income for SRPT at -$5.3 million in Q4 2025, $48.0 million in Q3 2025, and $38.1 million in Q2 2025.